Erasca Q2 net loss $35.6M; cash $390.8M; pipeline on track for H2 catalysts

Erasca, Inc.

2022-Q2 EPS reported -$0.60

Net loss of $35.6M ($0.30 per share) vs $28.2M ($1.20) year ago; R&D expenses $27.5M, G&A $8.4M.
Cash, equivalents, and marketable securities $390.8M as of June 30, 2022; expected to fund operations into H2 2024.
Initial Phase 1b monotherapy data for ERAS-007 (HERKULES-1) and Phase 1 data for ERAS-601 (FLAGSHP-1) expected H2 2022.
IND filing for CNS-penetrant KRAS G12C inhibitor ERAS-3490 in KRAS G12C-mutant NSCLC expected H2 2022.
Entered clinical trial collaboration with Eli Lilly to evaluate cetuximab + ERAS-601; expanded leadership and board.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.